Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Olsen IH; Sørensen JB; Federspiel B; Kjaer A; Hansen CP; Knigge U; Langer SW; Thescientificworldjournal, 2012, vol. 2012, p 170496, ISSN 1537744x. ISBN 1537744x.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef